



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

## Lutetium (<sup>177</sup>Lu) chloride Billev

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
II/0005/G	This was an application for a group of variations.  B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure  B.II.d.2.a - Change in test procedure for the finished	07/11/2024		Annex II, Labelling and PL	

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



product - Minor changes to an approved test procedure				
B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier				
B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS				
B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure				
B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site				
B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site				
B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch				

	<p>release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/immunological medicinal products</p> <p>B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p> <p>B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.II.f.1.e - Stability of FP - Change to an approved stability protocol</p>				
PSUSA/10391/202312	Periodic Safety Update EU Single assessment - lutetium ( <sup>177</sup> Lu) chloride	05/09/2024	n/a		PRAC Recommendation - maintenance
IB/0003	B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation	17/10/2023	n/a		
IB/0002	B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size	24/01/2023	n/a		

IAIN/0001/G	<p>This was an application for a group of variations.</p> <p>A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs</p> <p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p>	14/11/2022	03/11/2023	SmPC, Annex II, Labelling and PL	
-------------	--	------------	------------	----------------------------------	--